Phil Mojsov Nussenzweig, MD PhD
LightNews LightNews
banner
pnussenzweig.bsky.social
Phil Mojsov Nussenzweig, MD PhD
@pnussenzweig.bsky.social
350 followers 1.4K following 0 posts
Infectious Diseases Fellow BWH & MGH
Posts Replies Media Videos
Reposted by Phil Mojsov Nussenzweig, MD PhD
contagionlive.bsky.social
#ICYMI The federal agency gave the nod to Meitheal Pharmaceuticals for its antibiotic, Contepo, an intravenous fosfomycin offering a new mechanism of action and a new option for adults with complicated urinary tract infections, including those caused by resistant Gram-negative pathogens.
#IDsky
FDA Approves IV Antbiotic, Contepo, for Complicated Urinary Tract Infections | Contagion Live
The federal agency gave the nod to Meitheal Pharmaceuticals for its antibiotic, Contepo, an intravenous fosfomycin offering a new mechanism of action and a new option for adults with complicated urina...
www.contagionlive.com
November 5, 2025 at 5:49 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
contagionlive.bsky.social
Jill Blumenthal, MD, MAS, offers some insights on the results from a subset of Gilead’s phase 3 PURPOSE 2 study. #IDsky #Medsky
No Negative Impact for Individuals Taking Lenacapavir and Gender-Affirming Hormone Therapy | Contagion Live
Jill Blumenthal, MD, MAS, offers some insights on the results from a subset of Gilead’s phase 3 PURPOSE 2 study.
www.contagionlive.com
October 29, 2025 at 8:04 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
academicmededu.bsky.social
Today's #MondayBites: Prof. Jen Manne-Goehler on promising therapeutic options for people living with #HIV (PLWHIV) with excessive #visceralfat.

Watch the full talk on our accredited e-learning module on Improving Metabolic Health in #PLWHIV!

🔗 amededu.co/3VVqMvH

#HIVSky #IDSky #MedSky #hiv247
October 27, 2025 at 2:56 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
harborucla-id.bsky.social
Shout out to sustainability leaders at Harbor-UCLA Pam Lee, MD and Gary Fong, PharmD with the launching of an Antibiotic Waste Calculator (ecorxchoice.com?page=home) as a innovative solution to support antibiotic stewardship and sustainability!
See recent newsletter @sidpharm.bsky.social

#IDSky
October 15, 2025 at 6:55 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
alainnajj.bsky.social
POV: Rheumatology, ID, and Heme/Onc on their way to investigate your fever of unknown origin (ID is Beyoncé) #IDsky
September 12, 2025 at 10:10 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
cvdall.bsky.social
A question for #IDsky folks: Are you calling it Candida auris or Candidozyma auris? The Europeans appear to be going with the latter.
September 11, 2025 at 4:23 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
bachynski.bsky.social
Walensky: “HHS leadership is inching towards a complete vaccine takedown, incrementally chiseling away at our previously trusted systems, leaving behind a shaky, fragmented vaccine facade that is increasingly obscure and untenable and that has already limited vaccine access”
CDC's vaccine information no longer entirely trustworthy, former director says
The former CDC director says vaccine information on CDC website is no longer entirely trustworthy and urges people to get vaccine guidance elsewhere.
www.statnews.com
September 5, 2025 at 8:37 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
absteward.bsky.social
Recent years have seen a dramatic rise in carbapenem-resistant K. pneumoniae which is now recognized as one of the most formidable MDR pathogens worldwide.
🆕🔥The mechanisms of antibiotic resistance & drug resistance transmission of Klebsiella pneumoniae #idsky
www.nature.com/articles/s41...
August 29, 2025 at 5:39 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
absteward.bsky.social
🆕🔥Streptococcal endocarditis: a meta-analysis of species dependant risk by 🌟s @drtoddlee.bsky.social
🌟Updated figure 🌟Infective endocarditis prevalence of streptococcal species vs. proportion of streptococcal species bacteraemia #idsky #EMIMCC
www.sciencedirect.com/science/arti...
August 25, 2025 at 4:18 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
darcy-id-doc.bsky.social
We are recruiting an Transplant ID faculty at WashU Medicine Infectious Diseases Division.

Come work at one of the largest transplant centers in the country with some of THE BEST ID fellows in the world!

facultyopportunities.wustl.edu/Posting/Deta...
August 11, 2025 at 1:54 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
citc-tb.bsky.social
#TBSky #IDSky
July 30, 2025 at 7:13 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
dralicehan.bsky.social
#IDsky
Fascinating study using ivermectin once a month during rainy season in children in Kenya 5-15 yrs of age as a mosquitocidal agent to reduce malaria by 27%

Management of malaria will end up being a multi pronged approach.

DOI: 10.1056/NEJMdo008089
July 24, 2025 at 11:47 AM
Reposted by Phil Mojsov Nussenzweig, MD PhD
tkes.bsky.social
📃Follow-up of UCSF's DoxyPEP trial published.

TL;DR
✅std care STI ↘️when started PEP -of course!🤷‍♂
✅no difference between arms for doxy R in N. gono 🥳
✅no change in S. aureus/MRSA carriage😅
❌doxy R in S. aureus ↗️ in doxy arm 😬
#AMR #AntimicrobialResistance #IDSky

www.thelancet.com/journals/lan...
Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension
Doxy-PEP was effective in reducing bacterial STIs in this population of men who have sex with men and transgender women, including during an open-label extension when doxy-PEP efficacy was known. Doxy...
www.thelancet.com
July 24, 2025 at 2:08 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
nejm.org
During 2018–2024, the percentage of 𝘕. 𝘨𝘰𝘯𝘰𝘳𝘳𝘩𝘰𝘦𝘢𝘦 isolates carrying 𝘵𝘦𝘵𝘔, which confers tetracycline resistance, increased from less than 10% to more than 30% across the United States. Full study results: nej.md/3GALFIE

#MedSky #IDSky
A graph showing the estimated percentage of isolates carrying tetM in a national surveillance dataset of N. gonorrhoeae from 2018 through the first quarter of 2024.
July 13, 2025 at 1:02 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
rmcarpiano.medsky.social
It's mosquito season in the US. With climate change, lack of an effective vaccine, & fed research cuts, there are worries dengue will become endemic to a larger part of N. America.

~3700 cases reported last yr in the contiguous US...All contracted abroad except 105 in CA, FL, or TX. 🛟😷 Medsky idsky
As Mosquito Season Peaks, Officials Brace for New Normal of Dengue Cases - California Healthline
In recent years, locally acquired dengue cases have appeared in California, Florida, and Texas, parts of the U.S. where the disease isn’t endemic. Health and vector control officials worry that with c...
californiahealthline.org
July 11, 2025 at 7:16 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
cidjournal.bsky.social
Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital

⭐️ Editor's Choice
#IDSky
Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital
There have been several recent reports of Clostridioides difficile infection (CDI) due to isolates with reduced fidaxomicin susceptibility (minimum inhibitory concentration [MIC] ≥ 2 µg/mL).
academic.oup.com
June 18, 2025 at 12:41 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
dbikard.bsky.social
I will be recruiting new postdocs with start dates end 2025 - early 2026. If you'd like to work at the Pasteur Institute in the heart of Paris surrounded by amazing scientists, reach out to discuss possible projects on SynBio / Bacterial Immunity!
May 18, 2025 at 3:20 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
absteward.bsky.social
🆕💫Multicenter matched cohort study
Among 8492 patients hospitalized patients with community-acquired pneumonia, azithromycin was associated with a lower mortality and more hospital free days compared to doxycycline in combination with beta-lactams #idsky #EMIMCC
academic.oup.com/cid/article-...
Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study
academic.oup.com
May 16, 2025 at 8:56 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
thekibosch.bsky.social
Recently, I put out a call for people to share their personal experiences with measles, mumps, rubella, and other vaccine-preventable diseases. I heard from dozens of people who discussed their own illnesses as well as those of friends, siblings, and patients. www.statnews.com/2025/05/10/w...
What it’s like to have measles, mumps, whooping cough, and other vaccine-preventable illnesses
STAT readers share what it's link to have measles, mumps, whooping cough, and other vaccine-preventable illnesses. Some stories are from decades past — others are quite recent.
www.statnews.com
May 10, 2025 at 1:54 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
paulsaxmd.bsky.social
One of the most challenging encounters in the outpatient practice of infectious diseases, summarized here wonderfully in @cidjournal.bsky.social by Drs. Advani and colleagues.
Have already used this algorithm several times!
doi.org/10.1093/cid/...
State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women
Abstract. Over 50% of adult women experience at least 1 urinary tract infection (UTI) in their lifetime, and almost one-quarter of them will experience a r
doi.org
April 29, 2025 at 9:46 AM
Reposted by Phil Mojsov Nussenzweig, MD PhD
umn-idim.bsky.social
Potent antifungals can trigger inflammation in immunosuppressed patients. Dr. Boulware highlights the need to assess immune status via the Damage-Response Framework to guide safe, effective treatment. 🧬 #IDSky
drboulware.bsky.social Dr. David Boulware, MD MPH @drboulware.bsky.social · Apr 26
@CIDJournal Publication
"Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the need for Individualized Immune-Based Strategies"

Immune status is an untapped key in treating infectious diseases. It's complicated, particularly in those without HIV
academic.oup.com/cid/advance-...
April 29, 2025 at 12:13 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
umn-idim.bsky.social
Dr. Boulware’s Ambition-CM trial shows promise for HIV-related cryptococcal meningitis. But for transplant patients, immune responses to antifungal therapy can be harmful. Personalized treatment is key. ⚠️🧠 #IDSky
Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the need for Individualized Immune-Based Strategies
Abstract. The promising results of the Ambition-CM trial in persons with HIV have sparked interest in treating non-HIV-associated cryptococcal meningitis w
academic.oup.com
April 29, 2025 at 12:13 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
tbfighters.org
A new TB vaccine in clinical trials was fully enrolled months ahead of schedule!🗓️ Early community engagement in TB hotspots made this possible. The global collaboration behind this project may deliver the first TB vaccine in over 100 years!🌎🌍🌏 #TBSky #IDSky
www.statnews.com/2025/04/28/m...
Major tuberculosis vaccine trial completes enrollment faster than expected
A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its enrollment target, ahead of expectations.
www.statnews.com
April 29, 2025 at 6:05 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
nejm.org
How good are we at preventing HIV? The latest episode of Beyond Journal Club, a collaboration between @coreimpodcast.bsky.social and NEJM Group, takes a deep dive into the PURPOSE trials, which look at the use of long-acting lenacapavir as PrEP. 🎧 Listen now: nej.md/4lDlNf2

#MedSky #IDSky
A visual representation of the PURPOSE 1 and 2 trials
April 18, 2025 at 1:38 PM
Reposted by Phil Mojsov Nussenzweig, MD PhD
scooper-id.bsky.social
As Antibiotic Resistance Surges, Gepotidacin Found Effective Against Gonorrhea
#IDSky #MedSky

The pill was effective against strains of gonorrhea bacteria that are resistant to existing antibiotics.

www.thelancet.com/journals/lan...
Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study
Gepotidacin demonstrated non-inferiority to ceftriaxone plus azithromycin for urogenital N gonorrhoeae, with no new safety concerns, offering a novel oral treatment option for uncomplicated urogenital...
www.thelancet.com
April 15, 2025 at 1:17 PM